NASDAQ:CORT - Corcept Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$18.09 +0.09 (+0.50 %)
(As of 05/24/2018 09:34 AM ET)
Previous Close$18.00
Today's RangeN/A
52-Week Range$10.40 - $25.96
Volume7,008 shs
Average Volume1.22 million shs
Market Capitalization$2.07 billion
P/E Ratio41.11
Dividend YieldN/A
Beta1.92

About Corcept Therapeutics (NASDAQ:CORT)

Corcept Therapeutics logoCorcept Therapeutics Incorporated, a pharmaceutical company, discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery, as well as develops CLIA-validated assay to measure FKBP5 gene expression. It is developing relacorilant that is in a Phase II trial to treat patients with Cushing's syndrome; abraxane in combination with relacorilant, which is in Phase I/II open label trial to treat solid tumors; and selective cortisol modulator CORT125281 combined with Xtandi that is in open label Phase I/II trial to treat patients with metastatic castration-resistant prostate cancer. The company is also developing CORT118335 selective cortisol modulator, which is in Phase I/II open label trial for the treatment of antipsychotic-induced weight gain and non-alcoholic steatotic hepatitis. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.

Receive CORT News and Ratings via Email

Sign-up to receive the latest news and ratings for CORT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:CORT
CUSIP21835210
Phone650-688-8803

Debt

Debt-to-Equity RatioN/A
Current Ratio5.44
Quick Ratio5.26

Price-To-Earnings

Trailing P/E Ratio41.11
Forward P/E Ratio24.78
P/E GrowthN/A

Sales & Book Value

Annual Sales$159.20 million
Price / Sales13.09
Cash Flow$0.4640 per share
Price / Cash38.99
Book Value$1.87 per share
Price / Book9.67

Profitability

EPS (Most Recent Fiscal Year)$0.44
Net Income$129.12 million
Net Margins75.05%
Return on Equity46.78%
Return on Assets39.56%

Miscellaneous

Employees136
Outstanding Shares115,240,000

Corcept Therapeutics (NASDAQ:CORT) Frequently Asked Questions

What is Corcept Therapeutics' stock symbol?

Corcept Therapeutics trades on the NASDAQ under the ticker symbol "CORT."

How were Corcept Therapeutics' earnings last quarter?

Corcept Therapeutics (NASDAQ:CORT) released its quarterly earnings data on Tuesday, May, 8th. The biotechnology company reported $0.19 earnings per share for the quarter, beating analysts' consensus estimates of $0.18 by $0.01. The biotechnology company earned $57.66 million during the quarter, compared to analyst estimates of $58.18 million. Corcept Therapeutics had a net margin of 75.05% and a return on equity of 46.78%. Corcept Therapeutics's revenue was up 108.9% compared to the same quarter last year. During the same period in the previous year, the business earned $0.06 EPS. View Corcept Therapeutics' Earnings History.

When is Corcept Therapeutics' next earnings date?

Corcept Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for Corcept Therapeutics.

What price target have analysts set for CORT?

5 equities research analysts have issued 1 year target prices for Corcept Therapeutics' shares. Their predictions range from $20.00 to $32.00. On average, they anticipate Corcept Therapeutics' share price to reach $26.40 in the next year. View Analyst Ratings for Corcept Therapeutics.

Who are some of Corcept Therapeutics' key competitors?

Who are Corcept Therapeutics' key executives?

Corcept Therapeutics' management team includes the folowing people:
  • Dr. Joseph K. Belanoff M.D., Co-Founder, CEO, Pres & Director (Age 61)
  • Mr. Gary Charles Robb, CFO, Chief Accounting Officer & Sec. (Age 55)
  • Dr. Robert S. Fishman M.D., ? F.C.C.P., Chief Medical Officer (Age 56)
  • Dr. Hazel Hunt Ph.D., Sr. VP of Research
  • Donald E. Laferle, Sr. VP

Has Corcept Therapeutics been receiving favorable news coverage?

Media coverage about CORT stock has been trending somewhat positive on Thursday, Accern Sentiment reports. Accern identifies positive and negative media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Corcept Therapeutics earned a coverage optimism score of 0.12 on Accern's scale. They also assigned press coverage about the biotechnology company an impact score of 48.22 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

Who are Corcept Therapeutics' major shareholders?

Corcept Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (11.20%), Federated Investors Inc. PA (11.01%), Dimensional Fund Advisors LP (1.37%), Northern Trust Corp (0.97%), Nexthera Capital LP (0.91%) and Russell Investments Group Ltd. (0.68%). Company insiders that own Corcept Therapeutics stock include David L Mahoney, G Leonard Baker Jr, Gary Charles Robb, James N Wilson, Joseph K Belanoff, Patrick G Enright, Renee D Gala and Robert S Fishman. View Institutional Ownership Trends for Corcept Therapeutics.

Which institutional investors are selling Corcept Therapeutics stock?

CORT stock was sold by a variety of institutional investors in the last quarter, including Prudential Financial Inc., Old Mutual Global Investors UK Ltd., Mckinley Capital Management LLC Delaware, PNC Financial Services Group Inc., Oak Ridge Investments LLC, Smith Asset Management Group LP, ClariVest Asset Management LLC and Russell Investments Group Ltd.. Company insiders that have sold Corcept Therapeutics company stock in the last year include David L Mahoney, G Leonard Baker Jr and Robert S Fishman. View Insider Buying and Selling for Corcept Therapeutics.

Which institutional investors are buying Corcept Therapeutics stock?

CORT stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Nexthera Capital LP, Dimensional Fund Advisors LP, GSA Capital Partners LLP, Timpani Capital Management LLC, ETRADE Capital Management LLC, State of Tennessee Treasury Department and Federated Investors Inc. PA. Company insiders that have bought Corcept Therapeutics stock in the last two years include Gary Charles Robb and Renee D Gala. View Insider Buying and Selling for Corcept Therapeutics.

How do I buy shares of Corcept Therapeutics?

Shares of CORT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Corcept Therapeutics' stock price today?

One share of CORT stock can currently be purchased for approximately $18.09.

How big of a company is Corcept Therapeutics?

Corcept Therapeutics has a market capitalization of $2.07 billion and generates $159.20 million in revenue each year. The biotechnology company earns $129.12 million in net income (profit) each year or $0.44 on an earnings per share basis. Corcept Therapeutics employs 136 workers across the globe.

How can I contact Corcept Therapeutics?

Corcept Therapeutics' mailing address is 149 COMMONWEALTH DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-688-8803 or via email at [email protected]


MarketBeat Community Rating for Corcept Therapeutics (CORT)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  288 (Vote Outperform)
Underperform Votes:  217 (Vote Underperform)
Total Votes:  505
MarketBeat's community ratings are surveys of what our community members think about Corcept Therapeutics and other stocks. Vote "Outperform" if you believe CORT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CORT will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Corcept Therapeutics (NASDAQ:CORT) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
5 Wall Street analysts have issued ratings and price targets for Corcept Therapeutics in the last 12 months. Their average twelve-month price target is $26.40, suggesting that the stock has a possible upside of 45.94%. The high price target for CORT is $32.00 and the low price target for CORT is $20.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.002.50
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $26.40$26.40$23.3333$19.25
Price Target Upside: 45.94% upside57.52% upside35.19% upside1.85% upside

Corcept Therapeutics (NASDAQ:CORT) Consensus Price Target History

Price Target History for Corcept Therapeutics (NASDAQ:CORT)

Corcept Therapeutics (NASDAQ:CORT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/13/2018Seaport Global SecuritiesInitiated CoverageBuy$32.00MediumView Rating Details
3/8/2018B. RileyInitiated CoverageBuy ➝ Buy$30.00LowView Rating Details
2/5/2018Piper Jaffray CompaniesSet Price TargetBuy$30.00HighView Rating Details
2/5/2018Stifel NicolausLower Price TargetBuy$25.00 ➝ $20.00LowView Rating Details
7/18/2017Ladenburg ThalmannSet Price TargetBuy$15.00 ➝ $20.00LowView Rating Details
12/20/2016Janney Montgomery ScottInitiated CoverageSell$7.00N/AView Rating Details
11/2/2016FBR & CoSet Price TargetBuy$12.00N/AView Rating Details
(Data available from 5/24/2016 forward)

Earnings

Corcept Therapeutics (NASDAQ:CORT) Earnings History and Estimates Chart

Earnings by Quarter for Corcept Therapeutics (NASDAQ:CORT)

Corcept Therapeutics (NASDAQ:CORT) Earnings Estimates

Current Year EPS Consensus Estimate: $0.73 EPS
Next Year EPS Consensus Estimate: $1.18 EPS

Corcept Therapeutics (NASDAQ CORT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/30/2018$0.20N/AView Earnings Details
5/8/2018Q1 2018$0.18$0.19$58.18 million$57.66 millionViewN/AView Earnings Details
2/22/2018Q4 2017$0.19$0.17$53.30 million$53.30 millionViewListenView Earnings Details
11/2/2017Q3 2017$0.13$0.11$41.64 million$42.70 millionViewN/AView Earnings Details
8/1/2017Q2 2017$0.08$0.10$31.37 million$35.56 millionViewN/AView Earnings Details
5/1/2017Q1 2017$0.03$0.04$25.53 million$27.60 millionViewListenView Earnings Details
3/6/2017Q4 2016$0.04$0.04$23.85 million$23.81 millionViewN/AView Earnings Details
11/1/2016Q316$0.01$0.02$21.24 million$21.70 millionViewN/AView Earnings Details
8/2/2016Q2 2016$0.01$0.01$18.33 million$19.72 millionViewN/AView Earnings Details
3/1/2016Q4 2015($0.02)$0.01$14.78 million$14.97 millionViewN/AView Earnings Details
1/28/2016Q415($0.02)$0.01$15.50 million$15.00 millionViewN/AView Earnings Details
11/5/2015Q315($0.02)($0.01)$13.90 million$13.30 millionViewN/AView Earnings Details
8/5/2015Q215($0.04)($0.02)$11.67 million$11.96 millionViewN/AView Earnings Details
5/7/2015Q115($0.04)($0.05)$10.50 million$10.10 millionViewN/AView Earnings Details
3/4/2015Q414($0.06)($0.03)$9.10 million$9.01 millionViewN/AView Earnings Details
11/4/2014Q214($0.07)($0.05)$7.62 million$7.28 millionViewN/AView Earnings Details
8/5/2014Q2 2014($0.11)($0.06)$5.85 millionViewN/AView Earnings Details
5/7/2014Q114($0.10)($0.13)$5.01 million$4.41 millionViewN/AView Earnings Details
3/5/2014Q413($0.10)($0.11)$4.01 million$4.10 millionViewN/AView Earnings Details
1/30/2014Q4($0.12)($0.10)ViewN/AView Earnings Details
11/7/2013Q313($0.12)($0.08)$2.70 million$2.60 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.11)($0.10)$2.72 million$1.90 millionViewN/AView Earnings Details
5/2/2013Q1 2013($0.09)($0.10)$2.48 million$1.72 millionViewN/AView Earnings Details
3/7/2013Q4 2012($0.09)($0.09)$1.50 million$1.38 millionViewN/AView Earnings Details
10/31/2012Q3 2012($0.09)($0.08)ViewN/AView Earnings Details
8/7/2012Q2 2012($0.11)($0.09)ViewN/AView Earnings Details
5/3/2012Q1 2012($0.11)($0.13)ViewN/AView Earnings Details
3/5/2012Q4 2011($0.09)($0.12)ViewN/AView Earnings Details
11/7/2011Q3 2011($0.10)($0.08)ViewN/AView Earnings Details
8/8/2011Q2 2011($0.09)($0.11)ViewN/AView Earnings Details
5/4/2011Q1 2011($0.11)($0.09)ViewN/AView Earnings Details
3/9/2011Q4 2010($0.10)($0.10)ViewN/AView Earnings Details
11/10/2010Q3 2010($0.10)($0.10)ViewN/AView Earnings Details
8/12/2010Q2 2010($0.09)($0.09)ViewN/AView Earnings Details
5/11/2010Q1 2010($0.08)($0.10)ViewN/AView Earnings Details
3/25/2010Q4 2009($0.11)($0.09)ViewN/AView Earnings Details
11/10/2009Q3 2009($0.10)($0.09)ViewN/AView Earnings Details
8/11/2009Q2 2009($0.11)($0.10)ViewN/AView Earnings Details
5/11/2009Q1 2009($0.10)($0.11)ViewN/AView Earnings Details
3/30/2009Q4 2008($0.12)($0.13)ViewN/AView Earnings Details
11/13/2008Q3 2008($0.13)($0.11)ViewN/AView Earnings Details
8/13/2008Q2 2008($0.12)($0.09)ViewN/AView Earnings Details
5/12/2008Q1 2008($0.15)($0.10)ViewN/AView Earnings Details
3/27/2008Q4 2007($0.10)($0.11)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Corcept Therapeutics (NASDAQ:CORT) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Corcept Therapeutics (NASDAQ CORT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 15.00%
Institutional Ownership Percentage: 76.46%
Insider Trading History for Corcept Therapeutics (NASDAQ:CORT)
Institutional Ownership by Quarter for Corcept Therapeutics (NASDAQ:CORT)

Corcept Therapeutics (NASDAQ CORT) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/11/2018G Leonard Baker JrDirectorSell30,000$16.01$480,300.00View SEC Filing  
5/7/2018Robert S FishmanInsiderSell8,000$17.68$141,440.008,000View SEC Filing  
4/6/2018Robert S FishmanInsiderSell8,000$16.22$129,760.008,000View SEC Filing  
3/7/2018Renee D GalaDirectorBuy10,000$15.51$155,100.001,000View SEC Filing  
3/7/2018Robert S FishmanInsiderSell8,000$15.67$125,360.008,000View SEC Filing  
2/7/2018Robert S FishmanInsiderSell8,000$16.60$132,800.008,000View SEC Filing  
1/8/2018Robert S FishmanInsiderSell8,000$18.67$149,360.008,000View SEC Filing  
12/8/2017Robert S FishmanInsiderSell8,000$16.72$133,760.008,000View SEC Filing  
11/13/2017G Leonard Baker JrDirectorSell30,000$17.59$527,700.00View SEC Filing  
7/19/2017David L MahoneyDirectorSell23,006$12.50$287,575.00View SEC Filing  
7/18/2017David L MahoneyDirectorSell6,091$12.50$76,137.50View SEC Filing  
7/13/2017David L MahoneyDirectorSell6,994$12.50$87,425.00View SEC Filing  
7/12/2017David L MahoneyDirectorSell6,510$12.50$81,375.00View SEC Filing  
5/4/2017Gary Charles RobbCFOBuy5,600$9.75$54,600.006,858View SEC Filing  
3/16/2017Patrick G. EnrightDirectorSell269,955$9.94$2,683,352.70View SEC Filing  
3/15/2017Patrick G EnrightDirectorSell600,000$10.15$6,090,000.00204,210View SEC Filing  
3/8/2017Patrick G EnrightDirectorSell750,000$9.75$7,312,500.00204,210View SEC Filing  
2/27/2017Patrick G EnrightDirectorSell2,500,000$8.81$22,025,000.00204,210View SEC Filing  
11/25/2016Patrick G EnrightDirectorSell36,941$9.34$345,028.94View SEC Filing  
11/21/2016Patrick G EnrightDirectorSell544,100$9.56$5,201,596.00View SEC Filing  
11/16/2016Patrick G EnrightDirectorSell174,847$9.55$1,669,788.85View SEC Filing  
11/11/2016James N WilsonDirectorSell158,812$8.51$1,351,490.12View SEC Filing  
11/11/2016Joseph K BelanoffInsiderSell500,000$8.98$4,490,000.002,464,195View SEC Filing  
11/7/2016Joseph K BelanoffCEOSell500,000$8.31$4,155,000.002,257,728View SEC Filing  
5/10/2016G Leonard Baker JrDirectorBuy100,000$4.88$488,000.00721,038View SEC Filing  
1/6/2016James N WilsonDirectorSell1,188$4.90$5,821.20View SEC Filing  
12/10/2015Daniel BradburyDirectorSell20,000$4.85$97,000.00View SEC Filing  
11/24/2015Daniel BradburyDirectorSell40,000$5.00$200,000.00View SEC Filing  
11/12/2015James N WilsonDirectorSell20,000$4.90$98,000.00View SEC Filing  
11/2/2015Steven LoVPSell12,500$4.00$50,000.0012,500View SEC Filing  
10/13/2015Steven LoVPSell53,033$3.82$202,586.06View SEC Filing  
10/7/2015Steven LoVPSell5,300$4.00$21,200.0053,033View SEC Filing  
10/6/2015Steven LoVPSell50,000$3.76$188,000.0058,333View SEC Filing  
9/16/2015Daniel BradburyDirectorSell20,000$4.96$99,200.00View SEC Filing  
9/1/2015James N WilsonDirectorSell10,000$4.90$49,000.00View SEC Filing  
8/27/2015Daniel BradburyDirectorSell20,000$4.76$95,200.00View SEC Filing  
7/21/2015Daniel BradburyDirectorSell10,000$4.98$49,800.00View SEC Filing  
7/20/2015Daniel BradburyDirectorSell10,000$5.32$53,200.00View SEC Filing  
7/8/2015David L MahoneyDirectorSell33,828$5.74$194,172.72View SEC Filing  
7/1/2015James N WilsonDirectorSell10,000$6.06$60,600.00View SEC Filing  
6/24/2015Daniel BradburyDirectorSell20,000$6.75$135,000.00View SEC Filing  
6/23/2015Daniel BradburyDirectorSell10,000$6.92$69,200.00View SEC Filing  
6/2/2015James N WilsonDirectorSell10,000$6.13$61,300.00View SEC Filing  
3/24/2015Patrick G EnrightDirectorSell1,089,745$5.75$6,266,033.75View SEC Filing  
3/19/2015Joseph C Cook JrDirectorSell77,200$5.22$402,984.00View SEC Filing  
6/11/2014G Leonard Baker JrDirectorBuy103,386$2.32$239,855.52View SEC Filing  
5/13/2014Joseph Cook, Jr.DirectorBuy100,000$1.84$184,000.002,040,826View SEC Filing  
5/12/2014Daniel BradburyDirectorBuy138,925$1.80$250,065.00View SEC Filing  
5/9/2014G Leonard Baker, Jr.DirectorBuy100,000$1.84$184,000.00578,389View SEC Filing  
5/2/2014Longitude Venture Partners L.PDirectorSell250,000$4.11$1,027,500.00View SEC Filing  
4/1/2014Patrick EnrightDirectorSell250,000$4.28$1,070,000.00View SEC Filing  
3/7/2014Longitude Venture Partners L.PDirectorSell250,000$4.00$1,000,000.00View SEC Filing  
3/14/2013Joseph L TurnerDirectorBuy10,000$2.01$20,100.00View SEC Filing  
12/5/2012G Leonard Baker JrDirectorBuy87,131$1.46$127,211.26View SEC Filing  
11/23/2012Daniel BradburyDirectorBuy179,000$1.39$248,810.00View SEC Filing  
11/7/2012G Leonard Baker JrDirectorBuy300,000$1.83$549,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Corcept Therapeutics (NASDAQ CORT) News Headlines

Source:
DateHeadline
Reader Inquiry: Whats In Store For Corcept Therapeutics?Reader Inquiry: What's In Store For Corcept Therapeutics?
seekingalpha.com - May 21 at 8:46 AM
Todays Research Reports on Trending Tickers: Nektar Therapeutics and Corcept TherapeuticsToday's Research Reports on Trending Tickers: Nektar Therapeutics and Corcept Therapeutics
finance.yahoo.com - May 21 at 8:46 AM
Corcept Therapeutics (CORT) Upgraded to "Buy" at BidaskClubCorcept Therapeutics (CORT) Upgraded to "Buy" at BidaskClub
www.americanbankingnews.com - May 19 at 1:01 PM
Corcept Therapeutics (CORT) Receives Consensus Recommendation of "Buy" from AnalystsCorcept Therapeutics (CORT) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - May 17 at 5:38 PM
Corcept Therapeutics Announces Presentations at the American Association of Clinical Endocrinologists 27th Annual CongressCorcept Therapeutics Announces Presentations at the American Association of Clinical Endocrinologists 27th Annual Congress
finance.yahoo.com - May 16 at 9:00 AM
Corcept Therapeutics (CORT) Director G Leonard Baker, Jr. Sells 30,000 SharesCorcept Therapeutics (CORT) Director G Leonard Baker, Jr. Sells 30,000 Shares
www.americanbankingnews.com - May 15 at 7:34 PM
Corcept Therapeutics (CORT) Upgraded by ValuEngine to BuyCorcept Therapeutics (CORT) Upgraded by ValuEngine to Buy
www.americanbankingnews.com - May 15 at 1:15 PM
Is the Options Market Predicting a Spike in Corcept Therapeutics (CORT) Stock?Is the Options Market Predicting a Spike in Corcept Therapeutics (CORT) Stock?
finance.yahoo.com - May 14 at 9:55 AM
Corcept Therapeutics (CORT) Downgraded to Hold at BidaskClubCorcept Therapeutics (CORT) Downgraded to Hold at BidaskClub
www.americanbankingnews.com - May 11 at 9:13 PM
Zacks: Brokerages Expect Corcept Therapeutics (CORT) Will Announce Quarterly Sales of $67.93 MillionZacks: Brokerages Expect Corcept Therapeutics (CORT) Will Announce Quarterly Sales of $67.93 Million
www.americanbankingnews.com - May 11 at 2:20 AM
Edited Transcript of CORT earnings conference call or presentation 8-May-18 9:00pm GMTEdited Transcript of CORT earnings conference call or presentation 8-May-18 9:00pm GMT
finance.yahoo.com - May 10 at 8:41 AM
Zacks: Brokerages Expect Corcept Therapeutics (CORT) to Announce $0.24 Earnings Per ShareZacks: Brokerages Expect Corcept Therapeutics (CORT) to Announce $0.24 Earnings Per Share
www.americanbankingnews.com - May 9 at 5:28 PM
Corcept Therapeutics (CORT) CEO Joseph Belanoff on Q1 2018 Results - Earnings Call TranscriptCorcept Therapeutics' (CORT) CEO Joseph Belanoff on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 9 at 8:37 AM
Corcept: 1Q Earnings SnapshotCorcept: 1Q Earnings Snapshot
finance.yahoo.com - May 9 at 8:37 AM
Corcept Therapeutics (CORT) Posts Quarterly  Earnings Results, Beats Estimates By $0.01 EPSCorcept Therapeutics (CORT) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPS
www.americanbankingnews.com - May 8 at 10:30 PM
Corcept Therapeutics (CORT) Insider Robert S. Fishman Sells 8,000 SharesCorcept Therapeutics (CORT) Insider Robert S. Fishman Sells 8,000 Shares
www.americanbankingnews.com - May 8 at 8:16 PM
Corcept Therapeutics Announces First Quarter 2018 Financial results and Provides Corporate UpdateCorcept Therapeutics Announces First Quarter 2018 Financial results and Provides Corporate Update
finance.yahoo.com - May 8 at 5:20 PM
JFs Core Biotech Buys #14: Introducing Our Final 2 Positions And Taking Advantage Of Weakness In The I-O SpaceJF's Core Biotech Buys #14: Introducing Our Final 2 Positions And Taking Advantage Of Weakness In The I-O Space
seekingalpha.com - May 8 at 8:40 AM
Corcept Therapeutics (CORT) Set to Announce Earnings on TuesdayCorcept Therapeutics (CORT) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - May 3 at 10:24 AM
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference CallCorcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
finance.yahoo.com - May 1 at 5:15 PM
Corcept Therapeutics Incorporated (NASDAQ:CORT): Is It A Good Long Term Opportunity?Corcept Therapeutics Incorporated (NASDAQ:CORT): Is It A Good Long Term Opportunity?
finance.yahoo.com - April 30 at 5:24 PM
Corcept Therapeutics (CORT) Lifted to "Buy" at Zacks Investment ResearchCorcept Therapeutics (CORT) Lifted to "Buy" at Zacks Investment Research
www.americanbankingnews.com - April 27 at 12:44 PM
UPDATE: Seaport Starts Corcept Therapeutics (CORT) at BuyUPDATE: Seaport Starts Corcept Therapeutics (CORT) at Buy
www.streetinsider.com - April 25 at 8:49 AM
$56.03 Million in Sales Expected for Corcept Therapeutics (CORT) This Quarter$56.03 Million in Sales Expected for Corcept Therapeutics (CORT) This Quarter
www.americanbankingnews.com - April 24 at 3:56 AM
Corcept Therapeutics (CORT) to Release Earnings on MondayCorcept Therapeutics (CORT) to Release Earnings on Monday
www.americanbankingnews.com - April 23 at 6:52 AM
Corcept Therapeutics (CORT) Given Average Recommendation of "Buy" by AnalystsCorcept Therapeutics (CORT) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - April 22 at 5:32 PM
Corcept Therapeutics (CORT) Expected to Post Earnings of $0.18 Per ShareCorcept Therapeutics (CORT) Expected to Post Earnings of $0.18 Per Share
www.americanbankingnews.com - April 22 at 11:15 AM
Corcept Therapeutics (CORT) Lifted to "Buy" at BidaskClubCorcept Therapeutics (CORT) Lifted to "Buy" at BidaskClub
www.americanbankingnews.com - April 20 at 11:39 AM
Should You Be Tempted To Buy Corcept Therapeutics Incorporated (NASDAQ:CORT) At Its Current PE Ratio?Should You Be Tempted To Buy Corcept Therapeutics Incorporated (NASDAQ:CORT) At Its Current PE Ratio?
finance.yahoo.com - April 18 at 8:53 AM
Corcept Therapeutics (CORT) Given a $20.00 Price Target by Ladenburg Thalmann AnalystsCorcept Therapeutics (CORT) Given a $20.00 Price Target by Ladenburg Thalmann Analysts
www.americanbankingnews.com - April 17 at 6:29 PM
Corcept Therapeutics (CORT) Lifted to "Strong-Buy" at BidaskClubCorcept Therapeutics (CORT) Lifted to "Strong-Buy" at BidaskClub
www.americanbankingnews.com - April 16 at 10:55 AM
10 Healthcare Stocks to Stave Off the Market Flu10 Healthcare Stocks to Stave Off the Market Flu
finance.yahoo.com - April 14 at 8:39 AM
Corcept Therapeutics (CORT) Now Covered by Seaport Global SecuritiesCorcept Therapeutics (CORT) Now Covered by Seaport Global Securities
www.americanbankingnews.com - April 13 at 11:01 AM
JFs Core Biotech Buys #10: Incyte Disappoints, Optimism Returns To Gene Therapy And A New PositionJF's Core Biotech Buys #10: Incyte Disappoints, Optimism Returns To Gene Therapy And A New Position
seekingalpha.com - April 10 at 8:32 AM
Insider Selling: Corcept Therapeutics (CORT) Insider Sells 8,000 Shares of StockInsider Selling: Corcept Therapeutics (CORT) Insider Sells 8,000 Shares of Stock
www.americanbankingnews.com - April 9 at 7:19 PM
Zacks Investment Research Downgrades Corcept Therapeutics (CORT) to HoldZacks Investment Research Downgrades Corcept Therapeutics (CORT) to Hold
www.americanbankingnews.com - April 7 at 4:58 PM
Corcept Therapeutics (CORT) Expected to Post Quarterly Sales of $56.54 MillionCorcept Therapeutics (CORT) Expected to Post Quarterly Sales of $56.54 Million
www.americanbankingnews.com - April 7 at 3:58 AM
Zacks: Brokerages Expect Corcept Therapeutics (CORT) to Announce $0.17 EPSZacks: Brokerages Expect Corcept Therapeutics (CORT) to Announce $0.17 EPS
www.americanbankingnews.com - April 5 at 11:37 AM
Piper Jaffray Analysts Give Corcept Therapeutics (CORT) a $30.00 Price TargetPiper Jaffray Analysts Give Corcept Therapeutics (CORT) a $30.00 Price Target
www.americanbankingnews.com - April 3 at 8:45 PM
Corcept Therapeutics (CORT) Rating Lowered to Hold at Zacks Investment ResearchCorcept Therapeutics (CORT) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - March 30 at 10:02 PM
BidaskClub Lowers Corcept Therapeutics (CORT) to HoldBidaskClub Lowers Corcept Therapeutics (CORT) to Hold
www.americanbankingnews.com - March 29 at 11:17 AM
Corcept Therapeutics Incorporated (CORT) Given Average Rating of "Buy" by BrokeragesCorcept Therapeutics Incorporated (CORT) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - March 28 at 5:41 PM
Corcept Therapeutics (CORT) Stock Rating Upgraded by BidaskClubCorcept Therapeutics (CORT) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - March 26 at 11:30 PM
Why Is Corcept Therapeutics (CORT) Up 5.3% Since Its Last Earnings Report?Why Is Corcept Therapeutics (CORT) Up 5.3% Since Its Last Earnings Report?
finance.yahoo.com - March 26 at 9:14 AM
Corcept Therapeutics (CORT) PT Set at $30.00 by Piper Jaffray CompaniesCorcept Therapeutics (CORT) PT Set at $30.00 by Piper Jaffray Companies
www.americanbankingnews.com - March 25 at 12:12 PM
Corcept Therapeutics (CORT) Downgraded to "Buy" at BidaskClubCorcept Therapeutics (CORT) Downgraded to "Buy" at BidaskClub
www.americanbankingnews.com - March 25 at 9:30 AM
Edited Transcript of CORT earnings conference call or presentation 22-Feb-18 10:00pm GMTEdited Transcript of CORT earnings conference call or presentation 22-Feb-18 10:00pm GMT
finance.yahoo.com - March 23 at 6:09 PM
$56.54 Million in Sales Expected for Corcept Therapeutics Incorporated (CORT) This Quarter$56.54 Million in Sales Expected for Corcept Therapeutics Incorporated (CORT) This Quarter
www.americanbankingnews.com - March 21 at 4:31 AM
 Brokerages Expect Corcept Therapeutics Incorporated (CORT) Will Post Earnings of $0.18 Per Share Brokerages Expect Corcept Therapeutics Incorporated (CORT) Will Post Earnings of $0.18 Per Share
www.americanbankingnews.com - March 19 at 11:34 AM
Corcept Therapeutics (CORT) Rating Increased to Buy at BidaskClubCorcept Therapeutics (CORT) Rating Increased to Buy at BidaskClub
www.americanbankingnews.com - March 17 at 6:44 PM

SEC Filings

Corcept Therapeutics (NASDAQ:CORT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Corcept Therapeutics (NASDAQ:CORT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Corcept Therapeutics (NASDAQ CORT) Stock Chart for Thursday, May, 24, 2018

Loading chart…

This page was last updated on 5/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.